国际医学科学组织理事会(CIOMS)第十工作组关于药物安全性的证据合成和Meta分析的报告摘要(一)

doi:10.19803/j.1672-8629.2020.02.12

中国药物警戒 ›› 2020, Vol. 17 ›› Issue (2): 121-125.
DOI: 10.19803/j.1672-8629.2020.02.12

国际医学科学组织理事会(CIOMS)第十工作组关于药物安全性的证据合成和Meta分析的报告摘要(一)

Jesse A. Berlin^1*, 方肖燕², 张勇晶²

1强生集团全球流行病学部,美国 08560;
2杨森中国研发中心流行病学部,上海 200233

收稿日期:2019-06-04 修回日期:2020-06-22 出版日期:2020-02-15 发布日期:2020-02-26
作者简介:Jesse A. Berlin,男,博士,流行病学与生物统计学。

A Summary of Report of the Council for International Organizations of Medical Sciences (CIOMS) Working Group X on Evidence Synthesis and Meta-Analysis for Drug Safety

Jesse A. BERLIN¹, FANG Xiaoyan², ZHANG Yongjing²

1Global Epidemiology, Johnson & Johnson. USA, 08560;
2Janssen China R&D, Epidemiology, Shanghai 200233, China

Received:2019-06-04 Revised:2020-06-22 Online:2020-02-15 Published:2020-02-26

摘要/Abstract

摘要： Meta分析是循证医学中最重要的定量研究方法,目前已被广泛应用于药物研发期间及上市后有效性的评估中。近年来Meta分析在药物安全性上的应用对于FDA的决策影响愈见显著,然而目前各方对于该应用的认识有限。因此,本文将介绍国际医学科学组织理事会CIOMS 第十工作组(CIOMS X)起草指南文件的目的和目标读者,并就Meta分析的定义,计划及执行过程中的要点进行简要介绍。

关键词: Meta分析, 药物安全性

Abstract: Meta-analysis is the most important quantitative method in evidence-based medicine and has been widely applied to assess the efficacy during (and after) drug development. Recently, Meta-analysis used in studying safety outcomes has had a major impact on clinical or drug regulatory decisions. However, due to the difference of study design between safety and efficacy study, there are currently a number of challenges to the use of Meta-analysis to study drug safety. Hence, this paper is intended to present the aims of the CIOMS X guidance document, including comments on the intended audiences for the document. We present the key issues in Meta-analysis for drug safety, focusing on Meta-analyses of randomized clinical trials.

Key words: Meta-analysis, drug safety

中图分类号:

R994.11

Jesse A. Berlin, 方肖燕, 张勇晶. 国际医学科学组织理事会(CIOMS)第十工作组关于药物安全性的证据合成和Meta分析的报告摘要(一)[J]. 中国药物警戒, 2020, 17(2): 121-125.

Jesse A. BERLIN, FANG Xiaoyan, ZHANG Yongjing. A Summary of Report of the Council for International Organizations of Medical Sciences (CIOMS) Working Group X on Evidence Synthesis and Meta-Analysis for Drug Safety[J]. Chinese Journal of Pharmacovigilance, 2020, 17(2): 121-125.

导出引用管理器 EndNote|Ris|BibTeX

链接本文: https://zgywjj.magtechjournal.com/CN/10.19803/j.1672-8629.2020.02.12

https://zgywjj.magtechjournal.com/CN/Y2020/V17/I2/121

参考文献

[1] CIOMS Working Group X. Evidence Synthesis and Meta-Analysis for Drug Safety: Report of CIOMS Working Group X[S/OL]. (2016)[2019-07-01]. https://cioms.ch/shop/product/evidence-synthesis-and-Meta-analysis-report-of-cioms-working-group-x/.
[2] Nissen SE, Wolski K.Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes[J]. N Engl J Med, 2007, 356(24): 2457-2471.
[3] Tucker ME. FDA Lifts Final Regulatory Restrictions on Rosiglitazone [EB/OL]. (2015-12-16) [2019-07-01]. http://www.medscape.com/viewarticle/856056.
[4] Yahav D, Paul M, Fraser A, et al.Efficacy and safety of cefepime: a systematic review and Meta-analysis[J]. Lancet Infect Dis, 2007, 7(5): 338-348.
[5] Kim PW, Wu Y-T, Cooper C, et al.Meta-Analysis of a Possible Signal of Increased Mortality Associated with Cefepime Use[J]. Clinical Infectious Diseases, 2010, 51(4): 381-389.
[6] U.S. Food and Drug Administration. Guidance for industry: Diabetes mellitus-evaluating cardiovascular risk in new antidiabetic therapies to treat Type 2 diabetes[EB/OL]. (2018-09-19) [2019-07-01]. http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM071627.pdf.
[7] U.S. Food and Drug Administration. Meta-Analyses of Randomized Controlled Clinical Trials to Evaluate the Safety of Human Drugs or Biological Products[EB/OL]. (2018-11-15) [2019-07-01]. https://www.fda.gov/regulatory-information/search-fda-guidance-documents/Meta-analyses-randomized-controlled-clinical-trials-evaluate-safety-human-drugs-or-biological.
[8] The European Network of Centres for Pharmacoepidemiology and Pharmacovigilance (ENCePP). Guide on Methodological Standards in Pharmacoepidemiology (Revision 6)[EB/OL].(2017-07) [2019-07-01]. http://www.encepp.eu/standards_and_guidances/meth-odologicalGuide.shtml.
[9] Crowe BJ, Xia HA, Berlin JA, et al.Recommendations for safety planning, data collection, evaluation and reporting during drug, biologic and vaccine development: a report of the safety planning, evaluation, and reporting team[J]. Clin Trials, 2009, 6(5): 430-440.
[10] PROSPERO. About PROSPERO[EB/OL]. [2019-07-01] http://www.crd.york.ac.uk/prospero/#aboutpage.
[11] O'neill R. Assessment of safety, in Biopharmaceutical Statistics for Drug Development[M]. Marcel Dekker, 1988:543-604.
[12] Gleser L, Olkin I.The handbook of research synthesis and Metaan-alysis[M]. New York: Russell Sage Foundation, 1994:357-376.

[1]	史琪, 王建新, 王桂杰, 陆悦阳, 主佳旭, 高蕊. 清气化痰丸治疗慢性阻塞性肺疾病急性加重的系统评价[J]. 中国药物警戒, 2025, 22(8): 914-919.
[2]	应婕, 徐霄龙, 李博, 刘腾文, 刘清泉. 金花清感颗粒治疗轻型流感临床应用的Meta分析[J]. 中国药物警戒, 2025, 22(8): 920-923.
[3]	刘逸宇, 李彦文, 王娇, 周文静, 彭雨蒙, 贺文彬, 李志勇. 治疗头痛中成药的功效语义挖掘及安全性分析[J]. 中国药物警戒, 2025, 22(6): 674-679.
[4]	范丽萍, 鲁姝, 孙慧媛. 西洋参茎叶总皂苷辅助治疗冠心病心绞痛的有效性和安全性Meta分析[J]. 中国药物警戒, 2025, 22(5): 570-574.
[5]	王凤鑫, 李磊, 黄徐睿, 赵芸, LING Ruby, 杨阳, 梁昌昊, 曾韵桃, 郑颖君, 唐元辰, 刘嘉涛, 王成祥, 文天才, 李平. 丹参饮治疗冠心病疗效及安全性的系统评价[J]. 中国药物警戒, 2025, 22(5): 575-579.
[6]	范丽萍, 鲁姝, 蔡悦萍, 万宇翔, 孙慧媛. 康莱特联合吉非替尼治疗中晚期肺癌的Meta分析及试验序贯研究[J]. 中国药物警戒, 2025, 22(3): 316-323.
[7]	李波, 徐柳, 谢雨晴, 王艺颖, 董帅, 廉洁, 李国栋, 曹卉娟. 中成药治疗新型冠状病毒感染安全性和有效性的伞状评价[J]. 中国药物警戒, 2025, 22(2): 155-161.
[8]	王萍, 曹卉娟, 李梦琪, 张国治, 刘建平, 金雪晶. “乌头-半夏”反药配伍对大鼠毒性研究的系统评价和Meta分析[J]. 中国药物警戒, 2025, 22(2): 177-182.
[9]	张静, 张恺, 易湛苗. 丹参酚酸制剂辅助治疗冠心病、心绞痛及脑梗死相关疾病有效性及安全性的系统评价[J]. 中国药物警戒, 2024, 21(8): 910-915.
[10]	刘倩, 李博, 疏欣扬. 蓝芩口服液联合抗菌药物治疗急性扁桃体炎有效性与安全性的系统评价与Meta分析[J]. 中国药物警戒, 2024, 21(8): 916-920.
[11]	刘淑佳, 张晓朦, 陈思颖, 蔡海丽, 张冰. 中药复方防治乳腺癌化疗药心脏毒性的系统评价[J]. 中国药物警戒, 2024, 21(11): 1209-1215.
[12]	刘倩, 胡晶, 李博, 杨小静. 荆花胃康胶丸联合四联疗法治疗幽门螺旋杆菌相关性胃炎的系统评价及Meta分析[J]. 中国药物警戒, 2023, 20(9): 1039-1045.
[13]	张蕾, 吕健, 谢雁鸣. 厚朴排气合剂治疗术后早期肠麻痹有效性和安全性的Meta分析[J]. 中国药物警戒, 2023, 20(7): 799-806.
[14]	成冯镜茗, 吕健, 谢雁鸣. 复方丹参喷雾剂/气雾剂治疗冠心病心绞痛有效性与安全性的Meta分析[J]. 中国药物警戒, 2023, 20(5): 536-543.
[15]	王国华, 黎晓蕾, 刘希萍, 董毅智, 臧琛, 徐鸿, 田纪祥, 赵静. 痰热清注射液雾化吸入治疗慢性阻塞性肺疾病Meta分析[J]. 中国药物警戒, 2023, 20(5): 544-552.

国际医学科学组织理事会(CIOMS)第十工作组关于药物安全性的证据合成和Meta分析的报告摘要(一)

A Summary of Report of the Council for International Organizations of Medical Sciences (CIOMS) Working Group X on Evidence Synthesis and Meta-Analysis for Drug Safety

PDF (PC)

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics